İmmun trombositopeni tedavisinde kullanılan bir ilaç olan eltrombopag pseudotrombositopeni nedeni olabilir mi ? Olgu sunumu
Refrakter İTP hastalarında trombosit yıkımındaki artış nedeniyle kemik iliğinde megakaryositler artmıştır. Bu artış ile birlikte megakaryositler ve trombositlerdeki morfolojik anormallikler örneğin; immatür megakaryosit sayısında artış, nukleus ve sitoplazmada dejeneratif değişiklikler mikroskopik incelemede saptanır. Bu nedenle periferik yayma incelemesi yanlış tedavilere yol açılmaması açısından önemlidir. Burada, hemogram cihazının saydığı trombosit değeri ile periferik yaymada sayılan trombosit değerinin farklı olduğu bir refrakter İTP olgusu sunulmuştur.
Eltrombopag, a drug used in the treatment of immune thrombocytopenia, might be cause of pseudothrombocytopenia? A case report
In refractory ITP patients, megakaryocytes increase in the bone marrow because of accelerated platelet destruction. Together with this increase in megakaryoctes, morphological abnormalities in megakaryocytes and platelets, e.g.an increase of immature megakaryocytes, degenerative changes of the nucleus and cytoplasm, are also observed in the peripheral blood smear. Therefore, peripheral blood smear examinations are important in preventing the wrong treatment. A refractory ITP case is presented here; where the automated haematological evaluation of the thrombocyte count differs from the thrombocyte count of the peripheral blood smear.
___
- Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995-1008.
- McMillan R. The pathogenesis of chronic immune thrombocytopenic purpura. Semin Hematol 2007;44:3-11.
- Stasi R, Del Poeta G, Stipa E, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic purpura. Blood 2007;110:2924-2930.
- Olsson B, Andersson PO, Jernas M, et al. T-cell- mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003;9:1123-1124.
- Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386-2393.
- Houwerzijl EJ, Blom NR, van der Want JJ, et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 2004;103:500-506.
- Kashiwagi H, Tomiyama Y. Pathophysiology and management of primary immune thrombocytopenia. Int J Hematol 2013;98:24-33.
- Kuter DJ. New thrombopoietic growth factors. Blood 2007;109:4607-4616.
- Erickson-Miller CL, DeLorme E, Tian SS, et al. Discovery and characterization of selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 2005;33:85-93.
- Psaila B, Bussel JB, Linden MD, et al. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood 2012;119:4066-4072.
- Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6 month, randomised, phase 3 study. Lancet 2011;377:393-402.
- Saleh MN, Bussel JB, Cheng G, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia (ITP): results of long-term, open-label EXTEND study. Blood 2013;121:537-545.